SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+8.08%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$275M
AUM Growth
+$275M
(+15%)
Cap. Flow
+$12.1M
Cap. Flow
% of AUM
4.41%
Top 10 Holdings %
Top 10 Hldgs %
40.4%
Holding
55
New
15
Increased
13
Reduced
16
Closed
8
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$15.6M |
| 2 |
Charles River Laboratories
CRL
|
$6.77M |
| 3 |
Edwards Lifesciences
EW
|
$6.69M |
| 4 |
Baxter International
BAX
|
$5.56M |
| 5 |
Avantor
AVTR
|
$5.47M |
Top Sells
| 1 |
HCA Healthcare
HCA
|
$7.5M |
| 2 |
Tenet Healthcare
THC
|
$7.36M |
| 3 |
Medtronic
MDT
|
$6.59M |
| 4 |
Zimmer Biomet
ZBH
|
$6.09M |
| 5 |
Universal Health Services
UHS
|
$5.02M |
Sector Composition
| 1 | Healthcare | 89.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cardinal Health
CAH
$35.5B
| $5.04M | 1.18% |
45,000
+5,000
| +13% | +$560K |
|
27
BioMarin Pharmaceuticals
BMRN
$11.2B
| $5.02M | 1.18% |
57,500
+2,500
| +5% | +$218K |
|
28
Encompass Health
EHC
$12.3B
| $4.96M | 1.16% |
60,000
-30,000
| -33% | -$2.48M |
|
29
UnitedHealth
UNH
$281B
| $4.95M | 1.16% |
10,000
| – | – |
|
30
DexCom
DXCM
$29.5B
| $4.86M | 1.14% |
35,000
-15,000
| -30% | -$2.08M |
|
31
Vertex Pharmaceuticals
VRTX
$100B
| $4.6M | 1.08% |
11,000
-1,500
| -12% | -$627K |
|
32
West Pharmaceutical
WST
$17.8B
| $3.96M | 0.93% |
+10,000
| New | +$3.96M |
|
33
Becton Dickinson
BDX
$55.3B
| $3.71M | 0.87% |
+15,000
| New | +$3.71M |
|
34
Option Care Health
OPCH
$4.65B
| $3.69M | 0.86% |
+110,000
| New | +$3.69M |
|
35
GE HealthCare
GEHC
$33.7B
| $3.64M | 0.85% |
+40,000
| New | +$3.64M |
|
36
Cigna
CI
$80.3B
| $3.63M | 0.85% |
10,000
-7,500
| -43% | -$2.72M |
|
37
Natera
NTRA
$23.1B
| $3.2M | 0.75% |
+35,000
| New | +$3.2M |
|
38
Maravai LifeSciences
MRVI
$350M
| $3.17M | 0.74% |
365,000
+159,759
| +78% | +$1.39M |
|
39
Revvity
RVTY
$10.5B
| $3.15M | 0.74% |
+30,000
| New | +$3.15M |
|
40
Medpace
MEDP
$13.4B
| $3.03M | 0.71% |
+7,500
| New | +$3.03M |
|
|
CTLT
41
DELISTED
CATALENT, INC.
CTLT
| $2.82M | 0.66% |
+50,000
| New | +$2.82M |
|
42
Stevanato
STVN
$6.28B
| $2.67M | 0.63% |
83,039
+3,039
| +4% | +$97.6K |
|
43
Teva Pharmaceuticals
TEVA
$21.1B
| $2.47M | 0.58% |
+175,000
| New | +$2.47M |
|
44
BioNTech
BNTX
$24B
| $2.31M | 0.54% |
+25,000
| New | +$2.31M |
|
45
Biogen
BIIB
$19.4B
| $2.16M | 0.51% |
10,034
-14,966
| -60% | -$3.23M |
|
46
Structure Therapeutics
GPCR
$1.11B
| $191K | 0.04% |
+4,464
| New | +$191K |
|
47
Cencora
COR
$56.5B
| – | – |
-20,000
| Closed | -$4.11M |
|
48
Quest Diagnostics
DGX
$20.3B
| – | – |
-30,000
| Closed | -$4.14M |
|
49
DaVita
DVA
$9.85B
| – | – |
-45,000
| Closed | -$4.71M |
|
50
Labcorp
LH
$23.1B
| – | – |
-15,000
| Closed | -$3.41M |
|